INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 440m ago
HOUSE PTR40m ago
SEC 13F39m ago
ROBINHOOD CHAIN39m ago
SEC FORM 4/Open-market saleVerified data

Russell Alan J sold EWTX

Director, Chief Scientific Officer · Edgewise Therapeutics, Inc. · Common Stock

Side
SELL
Value
$99K
Shares
2,273
Price
$43.68
Executed
Aug 12, 2026
Disclosed
Aug 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Aug 12 executedAug 14, 2026 disclosed

EWTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
29/ 100 · ROUTINE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+8 / 25

    $99K reported value · 6.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · EWTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    7,031 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    29
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Open-market sale
    		SELL$141K
    3,238 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    5,781 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    22
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Open-market sale
    		SELL$17K
    390 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    17
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    5,781 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    5
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Grant or award
    		A—
    32.5K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    5
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Grant or award
    		A—
    65.0K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    17
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    5,781 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    17
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    7,500 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    33
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Open-market sale
    		SELL$95K
    2,171 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    26
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Open-market sale
    		SELL$14K
    304 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    26
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Open-market sale
    		SELL$6,666
    150 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    33
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Open-market sale
    		SELL$108K
    2,475 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    7,500 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Grant or award
    		A—
    50.0K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Grant or award
    		A—
    100.0K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    NM
    Nofi MichaelChief Financial Officer
    EWTXEdgewise Therapeutics, Inc.
    Grant or award
    		A—
    24.4K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    NM
    Nofi MichaelChief Financial Officer
    EWTXEdgewise Therapeutics, Inc.
    Grant or award
    		A—
    48.8K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RJ
    Russell Alan JDirector, Chief Scientific Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    7,031 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DB
    Derakhshan BehradChief Business Officer
    EWTXEdgewise Therapeutics, Inc.
    Option exercise
    		M—
    5,781 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001853529-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 12, 2026
    Published
    Aug 14, 2026
    Ingested by INSIDER
    Nov 5, 02:22 UTC
    Last re-read
    Nov 5, 02:22 UTC

    Extracted facts

    Filer
    Russell Alan J
    Role
    Director, Chief Scientific Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Edgewise Therapeutics, Inc.
    Ticker
    EWTX
    Shares
    2,273
    Price per share
    $43.68
    Value
    $99,275
    Execution date (reported)
    Aug 12, 2026
    Owned after transaction
    31.9K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 2,273
    • Price: $43.6759

    = $99,275

    What this establishes

    Russell Alan J filed this Form 4 reporting a open-market sale of EWTX on Aug 12, 2026. It became public on Aug 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Scientific Officer
    Russell Alan Jcik:0001853529
    Issuer
    Edgewise Therapeutics, Inc.cik:0001710072

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.